Gender Differences in Survival in Idiopathic Pulmonary Fibrosis and Following Lung Transplant by Creel, Michael Eric
 GENDER DIFFERENCES IN SURVIVAL IN IDIOPATHIC PULMONARY FIBROSIS
AND FOLLOWING LUNG TRANSPLANT 
 
 
 
 
 
 
 
 
by 
Michael Eric Creel 
BA, Biology, University of North Carolina at Asheville, 1998 
MD, East Carolina University, 2004 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Master of Public Health 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
 
2007 
 
 ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
This thesis was presented 
by 
Michael Eric Creel 
 
 
It was defended on 
November 7, 2007 
and approved by 
 
Thesis Advisor:  
Joseph Schwerha, MD, MPH  
Professor  
Department of Environmental and Occupational Health  
Graduate School of Public Health  
University of Pittsburgh  
 
Committee Member: 
Emanuela Taioli, MD, PhD 
A. Palmer Professor of Cancer Prevention 
Professor of Epidemiology, Hematology, and Oncology 
Director, Division of Cancer Prevention and Population Science 
UPMC Cancer Pavilion 
 
Committee Member: 
Jay Harper, MD, MPH 
Medical Director Employee Health Services 
UPMC 
 
Committee Member: 
Luis Ortiz, MD 
Associate Professor 
Department of Environmental and Occupational Health  
Graduate School of Public Health  
University of Pittsburgh  
 iii 
Copyright © by Michael Creel 
2007 
Joseph Schwerha, MD, MPH 
 
 
 
 
 
GENDER DIFFERENCES IN SURVIVAL IN IDIOPATHIC PULMONARY 
FIBROSIS AND FOLLOWING LUNG TRANSPLANT 
 
Michael Creel, MPH 
University of Pittsburgh, 2007
 
Abstract  
Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive form of interstitial lung 
disease characterized by inflammation and abnormal tissue repair ultimately leading to decreased 
pulmonary function and death.  Risk factors for IPF are largely unknown and medical treatment 
offers a poor prognosis due to the lack of effective treatment options.   
Survival outcomes were analyzed for a cohort of 331 patients.  The median age at clinical 
evaluation for IPF was 69 years.  Subjects survived an average of 21.82 months after diagnosis, 
with a higher survival in females than in males.  Males had a risk 2.85 times higher than females 
of death. Subjects older than 69 years of age had a relative risk of dying of 1.6 in comparison to 
subjects younger than 69 years.    
Predictors of survival after lung transplant were also analyzed in a cohort of 990 lung 
transplanted patients. The overall survival was 41.6%, (41.5 % in males, and 41.8 % in females), 
the average length of the follow up was 45.84 + 51.98 months (range 0 to 282.47 months). 
Females tend to live longer than males: 50.75 + 55.41 months versus 40.64 + 47.60 months 
respectively. Males had a risk of dying during the follow up that was 1.18 (95% CI 1.01-1.40) 
relative to females, after adjusting for ethnicity, age, smoking status, diagnosis and donor 
characteristics. Females who had at least one full term pregnancy during their life had better 
survival rates than females who had no full term pregnancies. 
 iv 
 Our results of a better survival after lung transplant in females (particularly females with 
at least one pregnancy) support the hypothesis of a hormonal contribution to survival and of the 
development of immunotolerance after pregnancy. 
The public health significance includes the use of the current study as a model in 
understanding the role of immunity in cancer development. The age-adjusted incidence rate is 
555.8 per 100,000 men and 411.3 per 100,000 women per year (2000-2004), and the combined 
lifetime risk of cancer is approximately 1 in 2.  Thus, any further understanding of cancer causes 
would be worthwhile in cancer prevention and treatment efforts.  
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1.0  INTRODUCTION 
1.1 INTERSTITIAL LUNG DISEASE 
Interstitial lung disease consists of a group of lung disorders (Appendix A) characterized 
by dyspnea, diffuse parenchymal lung infiltrates, restrictive airway pattern, and diminished gas 
exchange.  The most common type of interstitial lung disease is idiopathic pulmonary fibrosis 
(IPF) [1].  IPF is a chronic and progressive form of interstitial lung disease characterized by 
inflammation and abnormal tissue repair (scarring).  Scarring consists of replacement of normal 
lung tissue with connective tissue, including collagen [2].   
1.2 IDIOPATHIC PULMONARY FIBROSIS 
Idiopathic pulmonary fibrosis is a progressive and ultimately fatal disease [3].  While the 
exact mechanisms for the development of IPF are unknown, it is widely believed that chronic 
inflammation is the underlying cause.  Repeated injury to alveoli is believed to result in alveolar 
basement membrane damage.  Physiological attempts to repair the basement membrane lead to 
an exudative process of macrophage and fibroblast recruitment within the alveolar spaces over 
time.  Inflammatory cell recruitment and additional neovascularization results in alveolar 
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airspace destruction and loss of alveolar architecture.  Eventually, progressive fibrosis results as 
increased fibroblasts lead to collagen production and creation of extracellular matrix [3].   
 2 
2.0  EPIDEMIOLOGY 
2.1 PREVALENCE 
The prevalence of IPF is not well defined, but ranges from 3 to 29 cases per 100,000 [1].  
A study in Bernalillo, New Mexico revealed a prevalence of 20.2 cases per 100,000 for males 
and 13.2 cases per 100,000 for females with IPF [4].  More cases of IPF have been reported in 
males; the ratio of IPF in males to females is estimated to range from 1:1 to 2:1 [1].  
Approximately two-thirds of patients worldwide with IPF were older than 60 at the time of 
presentation (mean age of diagnosis 66 years) [5].   
2.2 SURVIVAL 
The mean survival of IPF ranges from 2 to 4 yr (5-yr survival range, 30 to 50%) [4].  The 
median survival of IPF at three years is 50% [6].  For comparison, the median survival for COPD 
(FEV1 < 30% predicted) is 50% at 3 years and the median survival for lung cancer is 85% at 5 
years.  Thus, the prognosis of interstitial pulmonary fibrosis is very poor, even in comparison to 
lung cancer.  Older age at diagnosis of IPF leads to a poorer outcome, as does male gender, and 
certain radiographic findings (including the predominance of reticular abnormality or 
honeycombing on HRCT) [6]. 
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3.0  RISK FACTORS 
3.1 GENERAL 
Risk factors for poor outcome of patients with IPF include older age, cigarette smoking, 
and male gender.  Death from IPF is more common in males and increases with age [6, 7].  
Survival in IPF is shorter in men compared to women and the possibility of a gender difference, 
possibly genetic or hormonal, has been suggested [8], however, a paucity of data exists to 
illuminate the potential etiology of gender differences. 
3.2 SMOKING 
Cigarette smoking may augment the inflammatory process in IPF and is believed to 
enhance the rate of disease progression in IPF [9].  A high percentage of persons with IPF are 
smokers [10].  In one study, a history of ever smoking was associated with a 60% increased risk 
for development of IPF [10].  
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3.3 ENVIRONMENTAL EXPOSURES 
In addition to smoking, other occupational or environmental risk factors for IPF include 
working with livestock and exposure to wood dust [7].  Intrapulmonary deposition of hazardous 
dusts, especially metallic dusts, appears to play at least a partial role in initiating IPF [11]. Other 
associations with IPF have been implied such as Epstein Barr virus (EBV) and other 
environmental exposures including mineral dust (silica) [7, 10].  However, the majority of 
individuals sharing an environment do not develop IPF, suggesting a genetic predisposition [7] 
which has yet to be determined.  
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4.0  TREATMENT 
4.1 GENERAL  
The currently available medical treatments consist mainly of immunosuppressants, such 
as steroids and cytotoxic agents, which offer a poor prognosis for IPF patients.   Utilization of 
corticosteroids and/or immunosuppressive agents have been unsuccessful in the treatment of IPF 
and have not improved disease survival period [5].  The end-stages of IPF are characterized by 
severe pulmonary hypertension with cor pulmonale that often dose not improve with oxygen 
therapy [5].  The American Thoracic Society recommends that patients with significant 
deterioration should be considered for lung transplantation [4].    
4.2 TRANSPLANTATION 
Lung transplantation is recognized as a treatment option for patients with IPF.  
Transplantation can prolong life and improve quality of life in end-stage patients with severe 
respiratory insufficiency and who have failed medical treatment.  Single lung transplantation 
results in an actuarial survival of 73% at one year and 57% at three years [12].  Old age, 
concurrent medical conditions, and issues inherent to transplant (including shortage of donor 
organs and rejection) often preclude lung transplant as a treatment option. 
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 While current medical treatments offer a poor prognosis, lung transplantation has been 
demonstrated to have a median survival of approximately 36 months in IPF patients [13].  
Transplant often leads to improved lung function and exercise capacity and improved perception 
of quality of life; many transplant recipients are able to return to work in comparison to those 
patients who do not undergo transplant [14]. 
However, limitations for lung transplantation exist including the lack of available donor 
organs with waiting times being as much as 2 years or more [14].  Candidates for transplant must 
also meet strict criteria.  
4.2.1 Transplant Rejection 
The most common reason that lung transplant fails to be a more successful treatment in 
the long term is organ rejection.  One of the most common causes of organ rejection is fibrosis.  
Primarily, chronic lung rejection that is characterized by bronchiolitis obliterans syndrome 
(BOS) has become a major obstacle for the long-term survival of lung allograft recipients [12].  
Constrictive BOS is a rapidly progressive inflammation disorder of the small airways that causes 
severe airflow restriction.  The cause of BOS is believed to be repetitive episodes of acute 
rejection which lead to repeated inflammation and repair with excessive proliferation of 
granulation tissue and fibrosis [15].  Other risk factors postulated to contribute to BOS include 
chronic rejection directed against bronchiolar epithelium, CMV infection, and recipient/donor 
difference in HLA antigens leading to post-transplant HLA-antibody production [16].  One year 
after transplantation, approximately 30% of deaths are due to BOS and as many as 50% of lung 
recipients will have had BOS within 5 years after transplantation [14]. 
 7 
 8 
5.0  IMMUNOLOGY 
 
While the specific causes of IPF are unknown, it is well documented that various 
cytokines in the immune system have significant effect in the progression of fibrosis.  Various 
cytokines, chemokines, and immune mediators have been shown to play a role in the progression 
of pulmonary fibrosis.  Tumor growth factor beta-1 (TGF-β1) has a role in inflammation and 
connective tissue synthesis.  Interleukin-1 has been shown to increase pulmonary fibrosis as well 
as increasing the levels of TGF-β1.  TGF-β1 is a critical cytokine in the inflammatory and 
immune response involved in lung fibrosis and is believed to be the central mediator of tissue 
repair and fibrosis.  TGF-β1 is a chemotactic factor for fibroblasts, monocytes, and macrophages.  
TGF-β1 can induce the expression of itself, affects proliferation of epithelial cells, and induces 
epithelial cells to create connective tissue [17].  Monocytes and macrophages produce many of 
the key cytokines, but also TGF-β1.  Fibroblasts make collagens, glycosaminoglycans, reticular 
and elastic fibers, and glycoproteins found in the extracellular matrix creating the fibrotic 
network.  TGF-β1 is likely a critical immune modulator in IPF being found at levels 11-fold 
higher in IPF patients compared to control lung [18].   
IPF is a chronic and progressive disease with limited prospect for cure.  Primary medical 
treatment consists of immunosuppressive therapies while surgical treatment is primarily lung 
transplant.  Medical therapy attempts to target the immune system mediators such as cytokines 
and surgical therapies attempt to limit the host immune response thereby minimizing allograft 
rejection.  The immune system is the architect of the fibrosis of IPF as repetitive inflammatory 
responses lead to progressive collagen deposition and fibrosis ultimately leading to lung tissue 
that is too restricted to ventilate.   
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6.0  GENDER 
6.1 GENDER AND IMMUNOLOGY 
Much research and discussion has revolved around the immunological involvement in 
IPF, but little exploration into gender differences in the disease itself and as it relates to 
immunology exist.  
Women have a higher incidence of immunologically based illnesses (e.g. Systemic Lupus 
Erythematosus and Grave’s Disease) and have greater immune reactivity than males [2, 19].  Cell-
mediated immunity and natural killer (NK) cell activity are diminished during pregnancy, and 
menopausal women have increased release of interleukin-1 (IL-1) by monocytes [19].  In 
addition, many of the components of immune regulation are affected by circulating levels of 
estrogen. 
In kidney transplantation, women over 45 years of age have a decreased relative risk of 
chronic allograft failure in comparison to younger women and men, however, women have a 
higher relative risk of acute rejection [19].   
Experiments in which pulmonary fibrosis was induced in rats with bleomycin show that 
female rats had increased susceptibility to develop lung fibrosis and had higher mortality rates 
than males [2].  The female rats had higher levels of collagen precursors in lung tissue than 
males indicating greater lung inflammation and fibrosis, however, when the ovaries of the female 
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rats were removed (i.e. removing the source of estrogen), morbidity, mortality, cytokine 
expression, and fibrosis were diminished indicating that gender differences may, in fact, be 
related to hormonal differences [2]. 
6.2 PREGNANCY 
A Polish study indicates that pregnancy and lactation may be protectors of cell-mediated 
immunity as women age.  Multiparous elderly women (mean age 74) had a stronger lymphocyte 
reaction compared to nulliparous elderly women (mean age 77) and were, in fact, similar in 
immune reaction to young nulliparous women (mean age 26) [20].  T-cells differentiate and 
mature in the thymus.  Lactation following pregnancy increases prolactin levels in the female 
human and mouse.  The prolactin acts on immunocytes that promote the generation of thymus 
tissue, thus increasing the ability of immune cells to mature and circulate in the body; the process 
may be responsible for the long-lasting immunoenhancing effect of multiparity and lactation 
[20]. 
Pregnancy may confer protection against disease via hormonal changes or by increasing 
immunity through introduction of fetal antigens.  Pregnancy has been theorized to provide a 
protective effect in breast cancer as a result of changes in estrogen fractions during early 
reproductive life [21].  Additionally, the fetal antigen hypothesis has been a proposed mechanism 
by which women are naturally immunized against cancer antigens by antigens from their fetuses 
[22].  It could be possible that multiparity may further increase anti-antigen/antibody diversity 
through the introduction of different antigens (such as novel genetic material) with subsequent 
births.  Studies have provided evidence that pregnancy provides immunization to antigens found 
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in breast, ovarian, and endometrial cancer cells possibly due to protection gained from exposure 
to fetal antigens [22, 23].  Fetal-maternal immunization against cancer is a hypothesis that may 
be a possible answer to the gender differences in IPF as exemplified by the lower incidence of 
IPF in women as compared to men.  Thus, pregnancy may provide a protection mechanism, 
whether hormonal or immunological, for women against IPF.   
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7.0  SURVIVAL OUTCOMES IN IDIOPATHIC PULMONARY FIBROSIS  
7.1 MATERIALS AND METHODS 
The data were extracted from patient records at the Simmons Center for Interstitial Lung 
Diseases at UPMC.  All consecutive patients who referred to the Center for further evaluation 
and treatment, and had a diagnosis of Idiopathic Lung Fibrosis from 1982 to 2006 were included 
in this analysis (n=331). Demographics (gender, ethnicity, age at evaluation, smoking status) and 
clinical (Forced Vital Capacity - FVC and Diffusing Capacity of the Lung for Carbon Monoxide 
- DLCO) were extracted from an anonymous data set prepared for this purpose. 
DLCO is the rate of uptake of carbon monoxide (CO) per driving pressure of alveolar CO, 
and provides an objective measurement of lung function; FVC is the volume change of the lung 
between a full inspiration to total lung capacity and a maximal expiration to residual volume. For 
the purpose of this analysis, former and current smokers have been included in one category, 
called ever smokers. 
Information on patients’ follow up included the date of their last clinical visit, or the date 
of death or the date of loss at follow up, whichever came first. 
All patients signed an informed consent to be included in a research registry. 
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7.2 STATISTICS 
Categorical data are presented as frequencies, continuous variables as means and 
Standard Deviations. The statistical endpoint for survival analysis was death, while the time 
frame for this analysis was the date at initial evaluation at the Simmons Center for Interstitial 
Lung Diseases at UPMC (diagnosis of IPF) and the date of death or date of current status 
(November 10, 2006).  
Crosstabulations were created to identify relationships between variables via 2x2 tables. 
Pearson Chi-square was used to test for the significance of the relationship between 
variables associated with death.  Kaplan-Meier plots were generated to study the determinant of 
survival.  Univariate and multivariate hazard ratios with confidence intervals were calculated 
using maximum-likelihood proportional hazard models. This analysis allows the independent 
contribution of several factors (age at diagnosis, gender etc) to the risk of death.  All statistical 
analyses were done using Intercooled Stata (Version 8.2; Stata Corp LP, College Station, TX). 
 
7.3 PARTICIPANTS 
The study population (n = 331) included 201 males and 130 females, 313 of whom were 
Caucasians.  The age at clinical evaluation for IPF ranged from 27 to 88 years of age, with a 
median of 69 years.  Most of the patients were former smokers (n=218), with a large variability 
in their pulmonary function parameters at entry. At the time of this data collection and analysis, 
146 patients were known to be deceased. 
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Table 1 Demographic Characteristics of Participants (n=331) 
Variable N % 
Gender   
Male 201 60.7 
Female 130 39.3 
Ethnicity  
Caucasian 313 94.6 
Other/Unknown 18 0.4 
Smoking Status  
Current 7 2.1 
Former 218 65.9 
Never 95 28.7 
Unknown 11 3.3 
 Means + SD Range 
Age at Evaluation 68.02 + 9.57 27.5-88.6 
FVC (liters) 2.26 + 0.86     0.56 - 4.96 
DLCO (mlCO/min/mmHg) 9.74 + 4.42 2.77-31.7 
 
 
7.4 SURVIVAL ANALYSIS 
The overall survival of the population according to gender is reported in Figure 1. 
Subjects survived an average of 21.82 months (SD: 18.22 months) after diagnosis, with a higher 
survival in females (23.43 months) than in males (20.78 months).  
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The univariate analysis (Table 2) shows that the effect of gender on survival is more 
pronounced in subjects younger than 69 years of age then in those 69 or older. In younger 
subjects, each incremental1 increase in age corresponds to a 3% increased risk of death during 
the follow up. Other variables associated with survival were the pulmonary function parameters 
at entry. 
 
Figure 1 Kaplan-Meier overall survival estimates by gender 
 
The multivariate analysis shows that the independent factors contributing to survival are 
age at diagnosis, gender, and the parameters of pulmonary function at entry. 
                                                 
1 Incremental increases are any difference in age between study participants 
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Males have a risk 2.85 times higher than females of dying during the follow up, after 
controlling for age, pulmonary function, smoking and ethnicity. Subjects > 69 years of age have 
a relative risk of dying of 1.6 in comparison to subjects younger than 69 years (Table 3).    
 
 
Table 2 Association between selected variables and survival  
Univariate analysis 
Variable Hazard Ratio 95% Conf. Interval 
Gender 1.38   1.0, 2.0 
Gender if age < 69 at 
evaluation  
1.59    1.0, 2.7 
Gender if age > 69 at 
Evaluation 
1.23   
 
0.8, 1.9 
Ethnicity 1.28    0.5, 3.5 
Smoking_status 0.98  0.7, 1.4 
Age at Evaluation * 1.03    1.0, 1.0 
FVC at Evaluation * 0.71    0.6, 0.9 
DLCO at Evaluation* 0.91    0.9, 1.0 
* Continuous variable 
 
 
Table 3 Association between selected variables and survival 
Multivariate Analysis 
Variable Hazard Ratio** 95% Conf. Interval 
Gender (males/females) 2.85 1.7, 4.7 
Age at Evaluation 
(> 69 vs < 69 yrs) 
1.60 1.1, 2.4 
FVC at Evaluation (liters)* 0.64 0.5, 0.9 
DLCO 
(mlCO/min/mmHg) *
0.90 0.8, 1.0 
**Adjusted for smoking and ethnicity  
* Continuous variable 
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8.0  PREDICTORS OF SURVIVAL AFTER LUNG TRANSPLANT 
8.1 INTRODUCTION 
 
Results of clinical lung transplantation over the past two decades have progressively 
improved. However, lung transplant is still characterized by a low 5 year survival, as shown by 
various international data [24]. Single lung transplantation results in an actuarial survival of 73% 
at one year and 57% at three years [12]. 
 A re-analysis of the United Network for Organ Sharing (UNOS) database showed 
comparable short- and midterm survival for bilateral versus single lung transplants in patients 60 
years of age or older. Predictors of survival in this population were smoking and history of 
idiopathic pulmonary fibrosis [25]. 
It has been suggested that donor-recipient gender combination may affect lung transplant 
survival, with a selective advantage for female to female transplant [26].  Several hypotheses 
have been put forward in order to explain these differences, for example the role of female 
hormones in increasing immuno-response and wound healing [27-31]. 
Full term pregnancy is also responsible for changes in both hormonal and immuno 
responses [19, 21-23]. However, the role of full term pregnancies on transplant survival in 
females has never been considered. 
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Understanding the regulation of immune responses in pregnancy may lead to new 
therapeutic concepts in transplanted patients. The model could also be very useful in order to 
understand cancer etiopathogenesis, since mechanisms physiologically used for induction of 
tolerance by the fetus are frequently abused by pathogens or tumors intending to escape the 
host’s immune response [32]. 
A series of consecutive lung transplant patients have been analyzed in order to establish: 
a) if gender gives a selective advantage for survival after lung transplant, and b) if this advantage 
can be partly explained by full term pregnancies. 
8.2 MATERIALS AND METHODS 
This study was conducted on all consecutive patients who underwent a lung transplant at 
the University of Pittsburgh from May 28, 1982 to February 2, 2007.  Subjects with single lung, 
double lung and combined heart-lung transplant were included. There were 414 double lung 
transplants, 121 heart-lung transplants, and 445 single lung transplants. Demographics of the 
recipient (gender, ethnicity, age at transplant, smoking status), as well as the pathology 
underlying the need for a transplant were extracted from an anonymous data set prepared for this 
purpose. For females, we were able to gather information on a number of full term pregnancies. 
Six transplants were from living donors while the remainders were transplanted from 
cadaveric donors. Age and gender of the donor was also available. 
Information on patients’ follow up included the date of their last clinical visit, or the date 
of death or the date of loss at follow up, whichever came first. All patients have signed an 
informed consent to be included in a research registry. 
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Subjects underwent lung transplant for several underlying pathologies that were 
summarized into 7 groups for the purpose of this study. Pulmonary hypertension includes both 
primary and secondary hypertension, the latter being caused being secondary to a congenital 
heart defect. Lung fibrosis includes both primary lung fibrosis and lung fibrosis secondary to 
chemotherapy. All the connective tissue disorders were included in one group. 
8.3 STATISTICAL ANALYSIS 
Categorical data are presented as frequencies, continuous variables as means and 
Standard Deviations. The statistical endpoint for survival analysis was death, while the time 
frame for this analysis was the date at lung transplant, the date of death or date of current status 
(as of February 14, 2007).  
Cross-tabulations were created to identify relationships between variables via 2x2 tables. 
Pearson Chi-square was used to test for the significance of the relationship between 
variables associated with death.  Kaplan-Meier plots were generated to study the determinant of 
survival.   
Univariate and multivariate hazard ratios with confidence intervals were calculated using 
maximum-likelihood proportional hazard models. This analysis allows the independent 
contribution of several factors (age at diagnosis, gender etc) to the risk of death.  All statistical 
analyses were done using Intercooled Stata (Version 8.2; Stata Corp LP, College Station, TX). 
 20 
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8.4 RESULTS 
The population under study consisted of 990 lung transplanted patients. The 
characteristics of the subjects are reported in Table 4. The majority of the patients were 
Caucasians; the proportion of males was roughly half, and so was the proportion of subjects who 
were never smokers, with a variety of pathologies behind their transplant. Seventeen percent of 
the subjects suffered of emphysema or pulmonary hypertension, while roughly 15% underwent 
the transplant because of pulmonary fibrosis, either primary or secondary to a congenital heart 
disease. 
Table 4 Demographic Characteristics of Participants (n=990) 
Variable N % 
Gender   
Male 481 48.6
Female 509 51.4
Ethnicity   
Caucasian 886 89.5
African American 48 4.9 
Other 45 4.6 
Smoking Status †   
Never 502 50.6
U< U34.5 Pack Yrs 244 24.7
>34.5 Pack Yrs 244 24.7
Diagnosis Categories   
Pulmonary Fibrosis 149 15.1
COPD/ Emphysema 268 27.0
Cystic Fibrosis 134 13.5
α-1-Antitrypsin Def. 74 7.5 
Pulmonary Hypertension 173 17.5
CREST, sclerodermia, sarcoidosis, 
connective tissue disorders 
81 8.2 
Others* 111 11.2
† Smokers divided into  two groups based on median pack years of smoking 
* Others include: Bronchiectasis, Bronchoalveolar Cancer, BOOP, Obliterative 
Bronchiolitis, Graft vs. Host, Retransplant, Silicosis, Lymphangioleiomyomatosis, 
Dilated Myopathy: Ischemic or idiopathic, Eosinophilic Granuloma, Pulmonary 
embolism 
 
8.5 SURVIVAL ANALYSIS 
The overall survival was 41.6%, (41.5 % in males, and 41.8 % in females), the average 
length of the follow up was 45.84 + 51.98 months (range 0 to 282.47 months). Females tend to 
live longer than males: 50.75 + 55.41 months (range 0 to 262.5 months) versus 40.64 + 47.60 
months (range 0 to 282.47 months) respectively (Figure 2). 
 
Figure 2 Post–transplant survival according to gender
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Post-transplant survival curves are presented in Figure 3.  The average survival of the all 
population was 50.1 months, with variability among pathologies. Pulmonary hypertension and α-
1-Antitrypsin Deficiency were associated with the lowest five years survival, while emphysema 
and COPD were the pathologies with the highest five years survival (Table 5). Patients with lung 
fibrosis survived an average of 33.75 months after lung transplant, while patients with 
pulmonary hypertension survived 57.42 months on average. 
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0. 50
0. 75
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Figure 3 Post–transplant actuarial survival curves according to underlying diagnosis
 
Months
Black: Cystic fibrosis 
Blue: Lung fibrosis 
Orange: COPD/ Emphysema
Light blue: α-1 Antitrypsin Deficiency
Green: Pulmonary  Hypertension 
Pink: Connective tissue disorders
Gray: others 
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Table 5  Survival of patients undergoing lung transplant (according to diagnosis and gender) 
 
Diagnosis 5 year survival Overall survival in months 
mean U+U SD (range) 
Cystic Fibrosis 53% 50.07 U+U 54.73 (0- 222.67) 
COPD/Emphysema 57% 46.85 U+U 44.34 (0 - 239.27) 
Pulmonary hypertension 46% 57.42 U+U 70.87 (0 - 262.50) 
Lung fibrosis 52% 33.75 U+U 38.11 (0 - 161.87) 
α-1 antitrypsin deficiency 48% 42.75 U+U 44.31 (0 - 166.77) 
Connective tissue disorders 50% 32.40 U+U 35.94 (0.2 - 139.13) 
Others 53% 48.31 U+U 57.25 (0 - 282.47) 
Gender   
Male 43% 40.64 U+ U47.60 (0- 282.47) 
Female 52% 50.75 U+U 55.41 (0 - 262.5) 
 
Among the variables considered as predictors of survival, gender and ethnicity resulted to 
be significantly associated with outcome. 
Males had a risk of dying during the follow up that was 1.18 (95% CI 1.01-1.40) relative 
to females, after adjusting for ethnicity, age, smoking status, diagnosis and donor characteristics. 
The hazard ratio was 1.43 (95% CI 1.17-1.65) for Caucasians versus African Americans and 
Others (Table 6). 
Females who had at least one full term pregnancy during their life had better survival 
rates than females who had no full term pregnancies (Figure 4). 
Table 6 Independent contribution of several variables to the overall survival 
Variable Hazard Ratio 95% Confidence Interval 
Gender (males/females) 1.18 1.01-1.40 
Ethnicity (Caucasians/African 
Americans/others) 
1.40 1.17-1.65 
Smoking (>34.5 pk-yrs/U< U 34.5 pk-
yrs/never) 
0.96 0.85-1.08 
Age recipient (> 49.5/ U< U49.5 years) 1.02 0.84-1.25 
Diagnosis (7 categories) 1.00 0.97-1.07 
Donor/recipient gender match 1.02 0.92-1.14 
Age donor (> 49.5/ U< U49.5 years) 1.01 0.97-1.05 
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Figure 4 Post-transplant actuarial survival curves according to pregnancy history
 
8.6 DISCUSSION  
 
The statistical analysis of the IPF study group indicates that gender and age at evaluation 
are significant risk factors for mortality due to IPF.  Specifically, the present study found that 
men have a greater risk of death due to IPF, which is consistent with prior research [1, 8, 33].  
Prior studies [9, 10] have suggested that smoking is a potential risk factor for death in IPF 
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patients, however, smoking was not found to be a statistically significant risk factor in the 
present study population.   
Smoking appears to have no statistically significant effect on outcome in women less 
than age 69 at age of evaluation for IPF in the present cohort.  The cause of death for this age 
group could be dependent on variables that have been postulated by other researchers, i.e. 
hormones, parity.  Subsequent investigations may elucidate potential causative factors in IPF 
outcome.   
In order to answer the question as to why gender and age play a role in IPF mortality, 
certain information must be ascertained.  Other studies have suggested that hormones and/or 
parity in women may play a protective role in females; however, a study with sufficient data 
does not yet exist.  A study of IPF patients accounting for pregnancies and/or hormone levels is 
required to provide insight into the gender differences in the mortality of IPF patients.  Serum 
hormone levels and documented history of parity in women would be necessary study variables. 
The study on a large series of well-characterized lung transplanted patients demonstrates 
that females have significantly better survival than males. The result holds true after adjustment 
for several potential confounding factors, for example smoking and underlying pathology. In 
addition, women who carried at least a full term pregnancy in their lifetime have better survival 
than women who did not. 
The reasons for these preliminary observations need to be analyzed more in depth, but 
hypotheses for the differences in survival with gender and with full term pregnancy among 
women can be put forward.  
Pregnancy is associated with hormonal changes and immunotolerance through 
introduction of fetal antigens.  It is known that pregnancy provides a protective effect towards 
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breast cancer, and this protection has been attributed to changes in estrogen fractions and levels 
during early reproductive life [21].  Many of the components of immune regulation are affected 
by circulating levels of estrogen, thus linking the hormonal with the immunological hypothesis. 
The fetal antigen hypothesis has been a proposed mechanism by which women are 
naturally immunized against cancer antigens by antigens from their fetuses [22], and could apply 
to immunotolerance to solid organ transplants as well. It could be possible that multiparity may 
further increase anti-antigen/antibody diversity through the introduction of different antigens 
(such as novel genetic material) with subsequent births.  Cell-mediated immunity and natural 
killer (NK) cell activity are diminished during pregnancy, and menopausal women have 
increased release of interleukin-1 (IL-1) by monocytes [19].  
Studies have provided evidence that pregnancy is associated with the development of 
immunization to antigens found in breast, ovarian, and endometrial cancer cells possibly due to 
past exposure to fetal antigens [22, 23]. For example, it has been shown that early age at first 
birth, cycle lengths ≥ 30 days, and oral contraceptive use increased the likelihood of having anti-
MUC1 antibodies, a glycoprotein overexpressed in ovarian cancer [34]. 
Our results of a better survival after lung transplant in females, and among them in those 
who had at least a full term pregnancy support the hypothesis of a hormonal contribution to 
survival and of the development of immunotolerance after pregnancy.  
Unfortunately, no data on hormonal levels or on detailed reproductive history are 
available in this or other studies on transplanted patients.  Concerted efforts to create a 
prospective study which include detailed parity history and hormonal levels of the participants in 
further studies in this direction are warranted, in order to understand the mechanisms of immuno 
tolerance to a foreign body. This will help in developing a model for understanding the role of 
immunotolerance in cancer development.  
The age-adjusted incidence rate (2000-2004) of all types of cancer was 555.8 per 100,000 
men and 411.3 per 100,000 women per year [35] and the lifetime risk of cancer is 1 in 2.  Thus, 
any knowledge to further delineate the etiopathology of cancer causes would be worthwhile in 
prevention and treatment efforts and provide a significant benefit to public health. 
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APPENDIX A 
CLASSIFICATION OF INTERSTITIAL LUNG DISEASES 
Occupational and Environmental Diseases 
Silicosis 
Asbestosis 
Hard-metal pneumoconiosis 
Coal worker's pneumoconiosis 
Berylliosis 
Hypersensitivity Pneumonitis 
  Bird breeder's lung 
  Farmer's lung 
Connective Tissue Diseases 
Systemic lupus erythematosus  
Scleroderma 
Rheumatoid arthritis 
Dermatomyositis 
Ankylosing spondylitis 
Primary Diseases 
Sarcoidosis 
Broncholaveolar carcinoma 
Pulmonary lymphoma 
Acute respiratory distress syndrome 
Postinfectious 
Treatment-Related or Drug-Induced Diseases 
Antibiotics (nitrofurantoin, sulfasalazine) 
Antiarrhythmics (amiodarone, tocainide, propranolol) 
Anti-inflammatories (gold, penicillamine) 
Anticonvulsants (dilantin) 
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Chemotherapeutic agents (mitomycin C, bleomycin, busulfan, cyclophosphamide, chlorambucil, 
methotrexate, azathioprine, BCNU [carmustine], procarbazine) 
Therapeutic radiation 
Idiopathic Fibrotic Disorders 
Idiopathic pulmonary fibrosis 
Respiratory bronchiolitis 
Lymphocytic interstitial pneumonia (Sjögren's syndrome, connective tissue disease, AIDS, 
Hashimoto's thyroiditis) 
Autoimmune pulmonary fibrosis (inflammatory bowel disease, primary biliary cirrhosis, 
idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia) 
Other 
Bronchiolitis obliterans with organizing pneumonia (BOOP) 
 
Adapted from:  
 
Mason RJ, Broaddus VC, Murray JF, Nadel JA, editors. Mason: Murray & Nadel's Textbook of 
Respiratory Medicine. 4th ed. Philadelphia: Elsevier Saunders; 2005   
 
Reynolds HY.  Diagnostic and Management Strategies for Diffuse Interstitial Lung Disease. 
Chest 1998;113: 192-202 
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